Sandoz Tests Direct‑to‑Consumer Sales With Omnitrope Growth Hormone Biosimilar on July 06, 2026 Biosimilars Ditiocarb DTC generics Growth Hormone liraglutide Omnitrope Sandoz Study models +
Italy probes Biogen for allegedly hindering sales of rival's MS drug on May 28, 2026 AGCM Biogen investigation Stratify test Biogen Biogen Tysabri Sandoz Biosimilars Italy antitrust probe Biogen Italy health service MS drug natalizumab Sandoz Tyruko +
Sandoz Expands Biosimilar Collaboration with Samsung Bioepis, Targeting Takeda's Entyvio on March 18, 2026 Biosimilars Entyvio Partnership Samsung Bioepis Sandoz SB36 +
Sandoz Reorganizes for Biosimilars 'Golden Decade' Amid Patent Cliff Opportunities on March 12, 2026 acquisition Biosimilars golden decade reorganization Sandoz +
Sandoz Launches Tyruko (Natalizumab-Sztn), First Tysabri Biosimilar, in US After JCV Assay Delays on November 18, 2025 Approved Biological Assay Biosimilars JC Virus JCV Leukoencephalopathy, Progressive Multifocal Multiple Sclerosis Polpharma Biologics Progressive Sandoz Tyruko Tysabri United States Food and Drug Administration +
Regeneron and Sandoz Settle Eylea Biosimilar Patent Dispute on September 10, 2025 Approved Biosimilars Enzeevu Eylea launch Ophthalmology specialty patent settlement Regeneron Sandoz United States United States Food and Drug Administration +
Sandoz Challenges Amgen in Antitrust Lawsuit to Launch Enbrel Biosimilar in the U.S. on April 15, 2025 Amgen Approved Biological Factors Biosimilars competition Enbrel Erelzi etanercept Legal patent Market Rheumatoid Arthritis Sandoz United States United States Food and Drug Administration +